TY  - JOUR
AU  - Hergueta-Redondo, Marta
AU  - Sarrio, David
AU  - Molina-Crespo, Angela
AU  - Vicario, Rocio
AU  - Bernado-Morales, Cristina
AU  - Martinez, Lidia
AU  - Rojo-Sebastian, Alejandro
AU  - Serra-Musach, Jordi
AU  - Mota, Alba
AU  - Martinez-Ramirez, Angel
AU  - Angeles Castilla, Ma
AU  - Gonzalez-Martin, Antonio
AU  - Pernas, Sonia
AU  - Cano, Amparo
AU  - Cortes, Javier
AU  - Nuciforo, Paolo G.
AU  - Peg, Vicente
AU  - Palacios, Jose
AU  - Angel Pujana, Miguel
AU  - Arribas, Joaquin
AU  - Moreno-Bueno, Gema
PY  - 2016
DO  - 10.18632/oncotarget.10787
UR  - http://hdl.handle.net/10668/19435
T2  - Oncotarget
AB  - Around, 30-40% of HER2-positive breast cancers do not show substantial clinical benefit from the targeted therapy and, thus, the mechanisms underlying resistance remain partially unknown. Interestingly, ERBB2 is frequently co-amplified and...
LA  - en
PB  - Impact journals llc
KW  - HER2-positive breast cancer
KW  - gasdermin B
KW  - clinical behaviour
KW  - predictive biomarker
KW  - resistance to therapy
KW  - Her2 amplicon includes
KW  - Adjuvant chemotherapy
KW  - Trastuzumab emtansine
KW  - Survival
KW  - Growth
KW  - Receptor
KW  - Gsdml
KW  - Lapatinib
KW  - Therapy
KW  - Plus
TI  - Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer
TY  - research article
VL  - 7
ER  -